|
93 Companies |
|
118 Products |
|
118 Products |
|
88 Mechanisms of Action |
|
3 Trials |
|
1622 News |
|
| «12345678910111213...3233» |
- | Enrollment change, Trial withdrawal, Trial primary completion date: Comparison of Adding EMEND to PONV/PDNV Treatment Regimen (clinicaltrials.gov) - Jan 31, 2018
P=N/A, N=0, Withdrawn, Sponsor: University of Nebraska
N=300 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2011 --> Jan 2011
- | olanzapine / Generic mfg.
Enrollment change: Olanzapine in the Treatment of Patients With Anorexia Nervosa (clinicaltrials.gov) - Jan 30, 2018
P2, N=34, Completed, Sponsor: Ottawa Hospital Research Institute
N=300 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2011 --> Jan 2011 N=28 --> 34
- | Trial completion, Phase classification, Enrollment change, Trial primary completion date: Transvaginal Cholecystectomy Versus Laparoscopic Cholecystectomy in Patients With Biliary Colic (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=30, Completed, Sponsor: Yale University
N=28 --> 34 Enrolling by invitation --> Completed | Phase classification: P4 --> PN/A | N=20 --> 30 | Trial primary completion date: Mar 2013 --> Sep 2013
- | Trial completion, Trial primary completion date: A Randomized-controlled Study of a Cognitive-behavioral Intervention for Children With Functional Abdominal Pain (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=127, Completed, Sponsor: University of Potsdam
Enrolling by invitation --> Completed | Phase classification: P4 --> PN/A | N=20 --> 30 | Trial primary completion date: Mar 2013 --> Sep 2013 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2017
- | Acofide (acotiamide) / Zeria, Astellas
Phase classification: YM443 in Subjects With Functional Dyspepsia (clinicaltrials.gov) - Jan 10, 2018
P2b, N=416, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2017 Phase classification: P2 --> P2b
- |||| Acofide (acotiamide) / Zeria, Astellas
Trial completion: YM443 in Subjects With Functional Dyspepsia (clinicaltrials.gov) - Jan 9, 2018
P2b, N=416, Completed, Sponsor: Astellas Pharma Inc
Phase classification: P2 --> P2b No longer recruiting --> Completed
- | Trial completion, Trial primary completion date: Ghrelin With Anorexia Nervosa (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=20, Completed, Sponsor: Maastricht University Medical Center
No longer recruiting --> Completed Suspended --> Completed | Trial primary completion date: Apr 2009 --> Dec 2011
- | Trial completion, Trial primary completion date: Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - Dec 28, 2017
P=N/A, N=52, Completed, Sponsor: University of Kansas Medical Center
Suspended --> Completed | Trial primary completion date: Apr 2009 --> Dec 2011 Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Oct 2016
- | Trial completion, Enrollment change: Screening for Fabry Disease in a Pediatric Population at Risk (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=1422, Completed, Sponsor: University Hospital Heidelberg
Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Oct 2016 Active, not recruiting --> Completed | N=2000 --> 1422
- | ondansetron / Generic mfg.
Trial completion: AVERT: Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy (clinicaltrials.gov) - Dec 5, 2017
P2, N=52, Completed, Sponsor: University of Vermont
Active, not recruiting --> Completed | N=2000 --> 1422 Active, not recruiting --> Completed
- Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Trial primary completion date, Metastases: Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma (clinicaltrials.gov) - Dec 5, 2017
P2b, N=12, Terminated, Sponsor: St. Louis University
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Dec 2015
- | hydromorphone hydrochloride / Generic mfg.
Trial completion, Trial primary completion date, Surgery: Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery (clinicaltrials.gov) - Nov 27, 2017
P4, N=200, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Sep 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2016
- | Enrollment change, Trial withdrawal: An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients (clinicaltrials.gov) - Nov 24, 2017
P=N/A, N=0, Withdrawn, Sponsor: Penn State University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2016 N=42 --> 0 | Not yet recruiting --> Withdrawn
- Rezonic (casopitant) / GSK
Enrollment change: Cyclophosphamide Drug Interaction Study In Cancer Patients (clinicaltrials.gov) - Nov 18, 2017
P1, N=25, Terminated, Sponsor: GlaxoSmithKline
N=42 --> 0 | Not yet recruiting --> Withdrawn N=10 --> 25
- | Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma, Sancuso (granisetron) / Solasia
Phase classification: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy (clinicaltrials.gov) - Nov 17, 2017
P1, N=29, Terminated, Sponsor: University of Southern California
N=10 --> 25 Phase classification: P=N/A --> P1
- | ondansetron / Generic mfg., diphenhydramine / Generic mfg.
Enrollment change, Trial withdrawal, Surgery: RETCHES: Rescue Emetic Therapy for Children Having Elective Surgery (clinicaltrials.gov) - Nov 14, 2017
P=N/A, N=0, Withdrawn, Sponsor: Franklyn Cladis
Phase classification: P=N/A --> P1 N=1600 --> 0 | Recruiting --> Withdrawn
- | Enrollment change: Neural Links Between OCD and Anorexia (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=64, Completed, Sponsor: Stanford University
N=1600 --> 0 | Recruiting --> Withdrawn N=80 --> 64
- | Trial completion, Enrollment change, Trial primary completion date, HEOR: Quality of Life (QOL), Coping and Psychological Symptoms in Children and Adolescents With Cyclic Vomiting Syndrome (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=61, Completed, Sponsor: Medical College of Wisconsin
N=80 --> 64 Active, not recruiting --> Completed | N=120 --> 61 | Trial primary completion date: Dec 2017 --> Jul 2017
- | Trial completion, IO biomarker: Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D (clinicaltrials.gov) - Oct 18, 2017
P=N/A, N=15, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=120 --> 61 | Trial primary completion date: Dec 2017 --> Jul 2017 Active, not recruiting --> Completed
- | Trial completion: Randomised Controlled Study on the Use of Psychoeducation for Bulimia Nervosa in Young Women (clinicaltrials.gov) - Oct 2, 2017
P=N/A, N=150, Completed, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | metyrosine / Generic mfg., diphenhydramine / Generic mfg.
Trial primary completion date: Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls (clinicaltrials.gov) - Sep 28, 2017
P=N/A, N=60, Suspended, Sponsor: University of Bern
Active, not recruiting --> Completed Trial primary completion date: May 2017 --> May 2019
- | Trial completion: Constipation Fiber Trial (clinicaltrials.gov) - Sep 28, 2017
P=N/A, N=60, Completed, Sponsor: Warren Bishop
Trial primary completion date: May 2017 --> May 2019 Recruiting --> Completed
- | Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma, Sancuso (granisetron) / Solasia
Trial primary completion date: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy (clinicaltrials.gov) - Sep 14, 2017
P=N/A, N=29, Terminated, Sponsor: University of Southern California
Recruiting --> Completed Trial primary completion date: Sep 2017 --> May 2017
- | Enrollment closed, Trial primary completion date: FAKT: Treatment of Eating Disorders by Physical Activity and Nutrition Counseling (clinicaltrials.gov) - Sep 7, 2017
P=N/A, N=128, Active, not recruiting, Sponsor: Norwegian School of Sport Sciences
Trial primary completion date: Sep 2017 --> May 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2018
- |||| Entereg (alvimopan) / Merck (MSD)
Trial completion: Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication (clinicaltrials.gov) - Aug 29, 2017
P2b, N=233, Completed, Sponsor: Cubist Pharmaceuticals LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2018 No longer recruiting --> Completed
- | olanzapine / Generic mfg.
Trial completion: Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa (clinicaltrials.gov) - Aug 25, 2017
P=N/A, N=152, Completed, Sponsor: New York State Psychiatric Institute
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Cluster Randomised Trial of Improved Sanitation in Rural Orissa, India (clinicaltrials.gov) - Aug 24, 2017
P=N/A, N=100, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial primary completion date: WASHB-Kenya: WASH Benefits Kenya (clinicaltrials.gov) - Aug 14, 2017
P=N/A, N=8246, Completed, Sponsor: Innovations for Poverty Action
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> Jul 2016
- | Trial completion, Enrollment change, Trial primary completion date: Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea (clinicaltrials.gov) - Aug 14, 2017
P=N/A, N=19, Completed, Sponsor: Medical College of Wisconsin
Trial primary completion date: Nov 2016 --> Jul 2016 Active, not recruiting --> Completed | N=50 --> 19 | Trial primary completion date: Jun 2018 --> Sep 2016
- || Trial initiation date, Trial primary completion date: Capsule Endoscopy for Hemorrhage in the Emergency Room (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: Andrew C. Meltzer, MD
Active, not recruiting --> Completed | N=50 --> 19 | Trial primary completion date: Jun 2018 --> Sep 2016 Initiation date: Mar 2017 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Aug 2018
- | Amitiza (lubiprostone) / Takeda, Mallinckrodt
Trial completion, Enrollment change, Trial primary completion date: Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit (clinicaltrials.gov) - Jul 27, 2017
P4, N=25, Completed, Sponsor: University of Louisville
Initiation date: Mar 2017 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Aug 2018 Active, not recruiting --> Completed | N=20 --> 25 | Trial primary completion date: Sep 2010 --> May 2011
- | Trial completion, Enrollment change: The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia (clinicaltrials.gov) - Jul 27, 2017
P4, N=128, Completed, Sponsor: Osaka City University
Active, not recruiting --> Completed | N=20 --> 25 | Trial primary completion date: Sep 2010 --> May 2011 Recruiting --> Completed | N=460 --> 128
- | Enrollment closed, Enrollment change: UCAN2: Uniting Couples in the Treatment of Anorexia Nervosa (clinicaltrials.gov) - Jul 25, 2017
P=N/A, N=60, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | N=460 --> 128 Recruiting --> Active, not recruiting | N=100 --> 60
- | alfuzosin hydrochloride / Generic mfg.
Enrollment closed: Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions (clinicaltrials.gov) - Jul 21, 2017
P2, N=72, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=100 --> 60 Recruiting --> Active, not recruiting
- | Trial completion, Phase classification: Mechanism of Action of Biofeedback Therapy (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=50, Completed, Sponsor: Augusta University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Phase classification: P2 --> PN/A
- ||||||| Acofide (acotiamide) / Zeria, Astellas
Trial completion, P3 data: Phase III, Long-term, Open-label Safety Study of Z-338 (clinicaltrials.gov) - Jun 28, 2017
P3, N=207, Completed, Sponsor: Zeria Pharmaceutical
Active, not recruiting --> Completed | Phase classification: P2 --> PN/A Active, not recruiting --> Completed
- | Trial completion: Alternative Approaches for Nausea Control (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=242, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Completed
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=45, Recruiting, Sponsor: Augusta University
Recruiting --> Completed Trial primary completion date: Feb 2016 --> Aug 2017
- | Enrollment change: A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain (clinicaltrials.gov) - Jun 21, 2017
P2, N=4, Terminated, Sponsor: University of Michigan
Trial primary completion date: Feb 2016 --> Aug 2017 N=40 --> 4
- | Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=29, Completed, Sponsor: Milton S. Hershey Medical Center
N=40 --> 4 Not yet recruiting --> Completed | N=50 --> 29 | Initiation date: Nov 2008 --> Jun 2009 | Trial primary completion date: Dec 2009 --> Jun 2010
- ||||||| Aemcolo (rifamycin SV MMX) / Cosmo Pharma, RedHill, Dr Falk
Trial completion, Trial primary completion date: ERASE: Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea (clinicaltrials.gov) - May 30, 2017
P3, N=835, Completed, Sponsor: Dr. Falk Pharma GmbH
Not yet recruiting --> Completed | N=50 --> 29 | Initiation date: Nov 2008 --> Jun 2009 | Trial primary completion date: Dec 2009 --> Jun 2010 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jan 2016
- |||| ondansetron / Generic mfg., temozolomide / Generic mfg.
Trial completion, Trial initiation date, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - May 30, 2017
P2, N=136, Completed, Sponsor: Katy Peters
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jan 2016 Recruiting --> Completed | Initiation date: Dec 2012 --> Jun 2014
- | Trial completion, Enrollment change, Trial primary completion date: Internet-delivered CBT for Functional Abdominal Pain in Adolescents - a Pilot (clinicaltrials.gov) - May 16, 2017
P=N/A, N=31, Completed, Sponsor: Karolinska Institutet
Recruiting --> Completed | Initiation date: Dec 2012 --> Jun 2014 Recruiting --> Completed | N=40 --> 31 | Trial primary completion date: Nov 2016 --> Jul 2016
- ||||||| cadazolid (ACT-179811) / J&J
Trial completion: Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (clinicaltrials.gov) - May 15, 2017
P3, N=631, Completed, Sponsor: Actelion
Recruiting --> Completed | N=40 --> 31 | Trial primary completion date: Nov 2016 --> Jul 2016 Active, not recruiting --> Completed
- | Trial completion, Enrollment change: PIM: Pediatric Integrative Medicine Trial Pilot (clinicaltrials.gov) - May 8, 2017
P3, N=872, Completed, Sponsor: University of Alberta
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=200 --> 872
- ||||||| aprepitant oral / Generic mfg.
Trial completion: Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) (clinicaltrials.gov) - May 4, 2017
P3, N=820, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=200 --> 872 No longer recruiting --> Completed
- |||| aprepitant oral / Generic mfg.
Trial completion: An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) (clinicaltrials.gov) - May 4, 2017
P4, N=866, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| ondansetron intravenous / Generic mfg., aprepitant oral / Generic mfg.
Trial completion: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) (clinicaltrials.gov) - May 4, 2017
P3, N=922, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| ondansetron intravenous / Generic mfg., aprepitant oral / Generic mfg.
Trial completion: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) (clinicaltrials.gov) - May 4, 2017
P3, N=805, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||| Biomarker, Trial completion, Head-to-Head: CACATU: Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD (clinicaltrials.gov) - May 4, 2017
P=N/A, N=355, Completed, Sponsor: University Medical Center Groningen
No longer recruiting --> Completed Active, not recruiting --> Completed